Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Left Ventricular Thrombus (R-DISSOLVE)
NCT04970381Completed
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivaroxaban in left ventricular thrombus (LVT), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Number of Participants With Left Ventricular Thrombus Resolution at 12 Weeks. Started Sep 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
left ventricular thrombus (LVT)
Beyond the preview
Go deeper on NCT04970381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970381.